Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15248196 | 0.79 | RPS6KA3 (0.39) | — | |
| SCHEMBL30236447 | 0.77 | AAK1 (0.38) | KRASSOS1 | |
| SCHEMBL29861446 | 0.77 | KRAS (0.31) | KRASSOS1 | |
| SCHEMBL23326471 | 0.77 | KRAS (0.31) | KRASSOS1 | |
| SCHEMBL24597146 | 0.77 | KRAS (0.31) | KRASSOS1 | |
| SCHEMBL4327782 | 0.76 | PDE2A (0.35) | — | |
| SCHEMBL23326793 | 0.76 | KRAS (0.33) | KRASSOS1 | |
| SCHEMBL23326796 | 0.76 | KRAS (0.33) | KRASSOS1 | |
| SCHEMBL24246883 | 0.74 | KRAS (0.35) | KRASSOS1 | |
| SCHEMBL23344933 | 0.73 | KRAS (0.34) | KRASSOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11247990-B1 | Bicyclic fused pyridine compounds as inhibitors of TAM kinases | ARRAY BIOPHARMA INC (US) | 2022-02-15 | — | — | US | disclosed |
| WO-2019113190-A1 | BICYCLIC FUSED PYRIDINE COMPOUNDS AS INHIBITORS OF TAM KINASES | ARRAY BIOPHARMA INC. (US) | 2019-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11247990-B1 | Bicyclic fused pyridine compounds as inhibitors of TAM kinases | MAP3K1, MAP3K3, MAP3K2 | KRAS 620/4885SOS1 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.